Quarterly report pursuant to Section 13 or 15(d)

Note 3 - Segment Information - Financial Information Relating to Reportable Segments (Details)

v3.3.0.814
Note 3 - Segment Information - Financial Information Relating to Reportable Segments (Details) - USD ($)
 3 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Biotechnology [Member] | Operating Segments [Member]    
Net sales $ 75,743,000 $ 76,453,000
Operating income 39,316,000 40,446,000
Consolidated operating income 39,316,000 40,446,000
Clinical Controls [Member] | Operating Segments [Member]    
Net sales 20,362,000 19,119,000
Operating income 4,711,000 6,108,000
Consolidated operating income 4,711,000 6,108,000
Protein Platforms [Member] | Operating Segments [Member]    
Net sales 16,296,000 12,914,000
Operating income (1,172,000) 2,604,000
Consolidated operating income (1,172,000) 2,604,000
Operating Segments [Member]    
Operating income 42,855,000 49,159,000
Consolidated operating income 42,855,000 49,159,000
Intersegment Eliminations [Member]    
Net sales (20,000) (9,000)
Corporate, Non-Segment [Member]    
Corporate general and administrative (965,000) (1,316,000)
Net sales 112,381,000 108,477,000
Operating income 31,028,000 35,216,000
Cost recognized on sale of acquired inventory (1,113,000) (3,167,000)
Amortization expense (7,411,000) (5,728,000)
Acquisition related expenses (301,000) (2,370,000)
Stock-based compensation (2,038,000) (1,362,000)
Corporate general and administrative (33,040,000) (28,701,000)
Consolidated operating income $ 31,028,000 $ 35,216,000